Corvus Pharmaceuticals CRVS Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $11.18M+49.9% | $9.94M+66.4% | $8.45M+61.9% | $7.87M+91.4% | $7.45M+82.9% | ||
| $3.7M+49.9% | $2.28M+6.9% | $2.12M+4.2% | $2.39M+31.1% | $2.47M+13.4% | ||
| $14.88M+49.9% | $12.22M+50.7% | $10.57M+45.7% | $10.26M+72.9% | $9.92M+58.7% | ||
| $14.88M+49.9% | $12.22M+50.7% | $10.57M+45.7% | $10.26M+72.9% | $9.92M+58.7% | ||
| -$14.88M-49.9% | -$12.22M-50.7% | -$10.57M-45.7% | -$10.26M-72.9% | -$9.92M-58.7% | ||
| $1.78M+240% | $603K+18.7% | $738K+30.4% | $639K+47.2% | $525K+66.1% | ||
| -$599K-11.1% | -$707K+67.5% | -$323K+52.6% | -$389K+32.6% | -$539K-328% | ||
| —— | —— | —— | —— | —— | ||
| -$13.09M-183% | -$11.61M-16.9% | -$9.83M+75.1% | -$7.61M-106% | $15.73M+365% | ||
| -$13.69M-190% | -$12.32M-1.7% | -$10.16M+74.7% | -$8M-87.7% | $15.19M+366% | ||
| -$0.15-15.4% | -$0.15+6.3% | -$0.12+80.0% | -$0.10-42.9% | -$0.13-8.3% | ||
| -$0.15-171% | -$0.15+6.3% | -$0.12+80.0% | -$0.10-42.9% | $0.21+275% | ||
| 90M+19.8% | 79.7M+30.8% | 82.8M+24.2% | 77.8M+30.3% | 75.2M+53.3% | ||
| 90M+24.8% | 79M+29.5% | 82.8M+24.2% | 77.8M+30.3% | 72.1M+47.1% | ||
| —— | —— | —— | —— | —— | ||
| -$13.92M-191% | -$12.16M+4.0% | -$10.07M+74.6% | -$7.89M-81.8% | $15.23M+353% | ||
| —— | —— | —— | —— | —— | ||
| $1.78M+240% | $603K+18.7% | $738K+30.4% | $639K+47.2% | $525K+66.1% | ||
| -$334K-1,352% | -$4K— | $29K-80.9% | -$19K-480% | -$23K-53.3% | ||
| $104K+82.5% | $168K+136% | $59K-87.3% | $125K+247% | $57K+119% | ||
| -$14.88M-49.9% | -$12.22M-50.7% | -$10.57M-45.7% | -$10.26M-72.9% | -$9.92M-58.7% | ||
| -$14.85M-50.0% | -$12.19M-50.8% | -$10.54M-45.8% | -$10.23M-73.0% | -$9.9M-58.9% | ||
| -$14.85M-50.0% | -$12.19M-50.8% | -$10.54M-45.8% | -$10.23M-73.0% | -$9.9M-58.9% | ||
| -$14.88M-49.9% | -$12.22M-50.7% | -$10.57M-45.7% | -$10.26M-72.9% | -$9.92M-58.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Corvus Pharmaceuticals profitable?
- Corvus Pharmaceuticals is not currently profitable: it reported a net loss of $44.2M over the trailing twelve months.
- What is Corvus Pharmaceuticals's earnings per share?
- Corvus Pharmaceuticals's diluted EPS over the trailing twelve months is $-0.52.
- Where does Corvus Pharmaceuticals's income statement data come from?
- Every line is extracted from Corvus Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.